Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

iCAD

Offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid an... read more Featured Products: More products

Download Mobile App




AI Solution Supporting Wins Best New Radiology Solution Award

By HospiMedica International staff writers
Posted on 18 Sep 2019
An FDA-cleared artificial intelligence (AI) solution that supports breast cancer detection in 3D tomosynthesis has been selected as the winner of “Best New Radiology Solution” Award in the 2019 MedTech Breakthrough Awards program.

ProFound AI for Digital Breast Tomosynthesis (DBT) from iCAD Inc (Nashua, NH, USA) is the first and only US FDA-cleared AI solution that supports breast cancer detection in DBT, or 3D mammography. More...
The technology is intended for use concurrently by radiologists reading DBT exams and uses a cutting-edge algorithm developed with the latest in deep learning.

Trained to detect malignant soft-tissue densities and calcifications, ProFound AI aids radiologists in breast cancer detection and is clinically proven to improve cancer detection rates, reduce false positives and unnecessary patient recalls, and decrease reading times for radiologists. The software rapidly and accurately analyzes each DBT image and provides radiologists with key information, such as Certainty of Finding and Case Scores, which assist radiologists in making clinical decisions and prioritizing caseloads.

ProFound AI for DBT runs on the PowerLook platform with NVIDIA graphical processing units (GPU). PowerLook is a flexible and reliable DICOM platform that easily integrates with image modalities, mammography review workstations, picture archiving and communication systems (PACS) and image storage systems. Leveraging the latest in GPU technology, the algorithm can rapidly process a four-view tomosynthesis case, ensuring results are available to radiologists in the most efficient manner.

“iCAD is a previous MedTech Breakthrough Award winner, and we are delighted to see the company continue to innovate. ProFound AI is a revolutionary technology built on the latest deep-learning and artificial intelligence technology that assists radiologists and addresses the challenges of reading breast tomosynthesis cases,” said James Johnson, managing director, MedTech Breakthrough. “We extend a hearty congratulations to the entire iCAD team on their innovative spirit and ability to execute on incorporating sophisticated AI technology in a platform that delivers incredibly real-world benefits.”



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.